Discussing the role of iPSCs in the manufacture of Cynata's Cymerus™ MSCs

Be the First to Comment Read
Sponsored

Discussing the role of iPSCs in the manufacture of Cynata's Cymerus™ MSCs

Cynata developing its Cymerus technology
Image source: Company website

Highlights

  • Cynata is using its proprietary Cymerus™ technology for the production of mesenchymal stem cells (MSCs)
  • Cymerus technology uses Nobel-Prize winning human-induced pluripotent stem cells (iPSCs) derived from whole blood for MSCs manufacture
  • iPSCs are unique due to their embryonic-like properties, their ability to be cultured indefinitely and be developed into almost any type of human cell

Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is developing its therapeutic stem cell platform technology, Cymerus™, to address the critical shortcoming in conventional methods of manufacturing mesenchymal stem cells (MSCs) - the ability to manufacture consistently and reproducibly at scale.

Cymerus is Cynata’s patented process of generating cell-based products from intermediate cells, termed as mesenchymoangioblasts (MCAs), that are derived from induced pluripotent stem cells (iPSCs).

Advantages of Cymerus technology

In this article, we will understand the role of induced pluripotent stem cells in the manufacture of MSCs.

Origin of iPSCs

iPSCs are obtained from mature cells found in the body such as blood or skin cells that have been reprogrammed back into an embryonic-like pluripotent state. One of the most versatile stem cells, a pluripotent stem cell can replicate itself indefinite times. It has the ability to differentiate into any other type of cell in the body.

Professor James Thomson and his team at the University of Wisconsin, Madison, including Professor Igor Slukvin (one of Cynata’s founders), were pioneers in the development of iPSCs. They were one of two independent research groups in 2007 that first reported the creation of iPSCs from human cells (together with Professor Shinya Yamanaka et. Al. of Kyoto University, Japan).

iPSCs are hailed as an ideal building block for cell-based therapies for their ability to expand without limit, produce tissue cells of any type, and be stored over long periods. And according to Cynata, this has significantly advanced the potential for regenerative therapy.

Do Read: Discussing competitive advantages of Cynata’s Cymerus technology

Importance of iPSC derived MSCs for Cymerus

Cynata’s Cymerus technology uses iPSCs derived from whole blood to produce MSCs as per Good Manufacturing Practice (GMP) standards at commercial scale. Since MCAs can expand themselves into extremely large quantities of MSCs, and iPSCs can proliferate indefinitely, Cynata expects to be able to source all the cells it will ever need from a single donor.

Cynata’s MSC manufacturing process

The Company intends to produce all the required cells from a single Master Cell Bank without the need for multiple donors or excessive culture expansion of the derived MSCs. A further series of patents have been licensed to Cynata by Cellular Dynamics International (now Fujifilm Cellular Dynamics, Inc.) relating to processes to derive iPSCs.

Overall, manufacturing of MSCs from iPSCs using the Cymerus technology could fix a significant limitation in existing methods of production of MSCs for therapeutic use and pave the way for a range of therapeutic and manufacturing opportunities for Cynata.

Cynata shares are trading at A$0.36 as of 12:45 PM AEST.

Good Read: Cynata Therapeutics: ASX-Listed Next-Generation Stem Cell Therapeutics Company

Disclaimer

Speak your Mind

Featured Articles

Ad
kalkine logo

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK